Brief: Roivant Sciences Q2 Operating Expenses USD 346.188 Million
12/11/2024 12:00
Nov 12 (Reuters) - Roivant Sciences Q2 EPS USD -0.31. * Q2 net income USD -279.924 million * Q2 income from operations USD -341.713 million vs. IBES estimate USD -250.9 million
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple